WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced the approval of a new compensation agreement. The company's Compensation Committee, consisting entirely of independent directors, has approved the grant of non-qualified stock options for the purchase of 175,000 shares of Viridian's common stock to a new employee. This Inducement Grant, dated July 1, 2025, is issued outside of the company's 2016 Equity Incentive Plan but adheres to its terms. The grant has an exercise price matching Viridian's stock closing price on the grant date and will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the next three years.